Clinical TrialAug 6, 2026, 04:24 PM
Structure Therapeutics Initiates Phase 3 Aleniglipron Program; Q2 Net Loss $106.2M
AI Summary
Structure Therapeutics announced the initiation of its Phase 3 ACCOMPLISH program for aleniglipron, an oral GLP-1 receptor agonist, marking a significant advancement in its chronic weight management pipeline. The company also reported its second-quarter 2026 financial results, with a net loss of $106.2 million, an increase from the prior year, driven by higher R&D expenses. Key pipeline updates include upcoming data readouts for aleniglipron and ACCG-2671, alongside the appointment of a new Chief Commercial Officer to bolster future commercialization efforts. The company's cash position of $1.3 billion is expected to fund operations through 2028.
Key Highlights
- First patients dosed in aleniglipron Phase 3 ACCOMPLISH program for chronic weight management.
- ACCG-2671 Phase 1 SAD data and MAD clinical trial initiation on track for Q3 2026.
- Topline 72-week aleniglipron ACCESS OLE data expected in Q3 2026.
- John Berrios appointed as Chief Commercial Officer.
- Cash, cash equivalents, and short-term investments totaled $1.3 billion as of June 30, 2026.
- Net loss for Q2 2026 was $106.2 million, compared to $61.7 million in Q2 2025.
- R&D expenses increased to $100.1 million in Q2 2026 from $54.7 million in Q2 2025.
- Current cash expected to fund operations and key clinical milestones through 2028.
Price Impact
More from GPCR